	US 11,999,783 B2
	Method of treating autoimmune disease with antibodies against IL-33
Robert A. Horlick, San Diego, CA (US); David J. King, Encinitas, CA (US); and Andrew John McKnight, San Diego, CA (US)
Assigned to AnaptysBio, Inc., San Diego, CA (US)
Filed by AnaptysBio, Inc., San Diego, CA (US)
Filed on Oct. 15, 2020, as Appl. No. 17/071,046.
Application 16/042,476 is a division of application No. 15/110,724, granted, now 10,059,764, issued on Aug. 28, 2018, previously published as PCT/US2015/010785, filed on Jan. 9, 2015.
Application 17/071,046 is a continuation of application No. 16/042,476, filed on Jul. 23, 2018, granted, now 10,836,820.
Claims priority of provisional application 61/925,946, filed on Jan. 10, 2014.
Prior Publication US 2021/0040198 A1, Feb. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/24 (2006.01)

CPC C07K 16/244 (2013.01) [C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

12 Claims

1. A method of treating an autoimmune disease using an interleukin-33 (IL-33) binding protein comprising an immunoglobulin heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 136, and an immunoglobulin light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 171.